Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma

Journal of the American College of Surgeons

Volumn 187, Issue 2, 1998, Pages 191-197

  Hsueh, Eddy C ^a   Gupta, Rishab K ^a   Glass, Edwin C ^a   Yee, Reynold ^a   Qi, Karen ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; DIAGNOSTIC IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OCCULT CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031876984     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(98)00140-9     Document Type: Article

References (26)

1. Karakousis CP, Velez A, and Driscoll BA. Metastasectomy in malignant melanoma. Surgery 1994;115:295-302.
2. Galicich JH, Sundaresan N, Arbit E, et al. Surgical treatment of single brain metastasis: factors associated with survival. Cancer 1980;45:381-386.
3. Morton DL, Joseph WL, Ketcham AS, et al. Surgical resection and adjunctive immunotherapy for selected patients with pulmonary metastases. Ann Surg 1973;178:360-366.
4. Tafra L, Dale PS, Wanek LA, et al. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995;110:119-128.
5. Buzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995;13:2104-2108.
6. Kirgan D, Guenther J, Bhattathiry M, et al. The importance of whole body PET exams on the management of metastatic malignant melanoma. Proc Am Soc Clin Oncol 1994;13:396.
7. Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-709.
8. Boni R, Boni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132:556-562.
9. Gritters LS, Francis IR, Zasadny KR, et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-1427.
10. Gupta RK, and Morton DL. Monoclonal antibody based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992;6:329-336.
11. Kelley MC, Jones RC, Gupta RK, Yee R, Stern S, Wanek L, Morton DL. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival in patients with earlystage melanoma. Cancer. In press.
12. Dahlbom M, Hoffman EJ, Hoh CK, et al. Evaluation of a positron emission tomography (PET) scanner for whole body imaging. J Nucl Med 1992;33:1191-1199.
13. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994;35:1771-1776.
14. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-444.
15. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
16. Braams JW, Prium J, Freling NJM, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211-216.
17. Stollfuss JC, Glatting G, Friess H, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995;195:339-344.
18. Crowley NJ, and Seigler HF. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg 1990;212:173-177.
19. Tsao H, Cosimi AB, and Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997;79:2361-2370.
20. Karp NS, Boyd A, DePan HJ, et al. Thoracotomy for metastatic malignant melanoma of the lung. Surgery 1990;107:256-261.
21. Branum GD, and Seigler HF. Role of surgical intervention in the management of intestinal metastases from melanoma. Am J Surg 1991;162:428-431.
22. Harpole DH, Johnson CM, Wolfe WG, et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 1992;103:743-750.
23. Wong JH, Skinner KA, Kim KA, et al. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993; 113:389-394.
24. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after specific active immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;316:463-482.
25. Legha S, and Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993;6(suppl 9):27-32.
26. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.